医学
经皮冠状动脉介入治疗
随机对照试验
支架
外科
心肌梗塞
临床终点
药物洗脱支架
随机化
内科学
作者
Robert A. Byrne,Róisín Colleran,J J Coughlan,Rajiv Jauhar,Luc Maillard,Axel de Labriolle,Michael Mæng,Charles B. Croft,Michael Brunner,David M. Leistner,Bernhard Zrenner,Marc Kollum,Karl‐Ludwig Laugwitz,Erion Xhepa,Katharina Mayer,Shqipdona Lahu,Michael Joner,Ajay J. Kirtane,Roxana Mehran,Mark Barakat,Philip Urban,Donald E. Cutlip,Adnan Kastrati
出处
期刊:Circulation-cardiovascular Interventions
[Ovid Technologies (Wolters Kluwer)]
日期:2024-10-01
卷期号:17 (10)
标识
DOI:10.1161/circinterventions.123.013735
摘要
BACKGROUND: Patients with an indication for oral anticoagulation who undergo percutaneous coronary intervention require a combination of oral anticoagulation and antiplatelet therapy. The use of a coronary stent with a thromboresistant and pro-healing coating may allow an abbreviated duration of dual antiplatelet therapy (DAPT) without an increase in the risk of thromboembolic events. METHODS: Patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention were randomized to treatment with the COBRA polyzene F (PzF) stent followed by 14 days of DAPT or a Food and Drug Administration–approved new-generation drug-eluting stent followed by 3 or 6 months of DAPT. The bleeding coprimary end point was Bleeding Academic Research Consortium type ≥2 beyond 14 days (or after hospital discharge) until 6 months. The thromboembolic coprimary end point was the composite of all-cause death, myocardial infarction, definite or probable stent thrombosis, or ischemic stroke at 6 months. The trial hypothesis was that the COBRA PzF stent strategy would be superior with respect to bleeding events and noninferior with respect to thromboembolic events. RESULTS: A total of 996 patients underwent randomization. The bleeding end point occurred in 37 of 475 patients (7.8%) in the COBRA PzF group and 47 of 482 patients (9.8%) in the control group (difference, −2.0 [95% CI, −5.6 to 1.6]; P =0.14). The thromboembolic end point occurred in 37 of 492 patients (7.5%) in the COBRA PzF group and 24 of 490 patients (4.9%) in the control group (difference, 2.6%; prespecified noninferiority margin 5%, upper limit of 1-sided 95% CI of the difference, 5.2%; P noninferiority =0.07). CONCLUSIONS: In patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention, treatment with the COBRA PzF stent plus 14 days of DAPT was not superior with respect to bleeding events and was not noninferior with respect to thromboembolic events at 6 months compared with treatment with standard Food and Drug Administration–approved drug-eluting stent plus 3 to 6 months of DAPT. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02594501.
科研通智能强力驱动
Strongly Powered by AbleSci AI